CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Guangdong Hybribio Biotech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Guangdong Hybribio Biotech Co Ltd
Community D5-3-3-4, North High-Tech Zone
Economic Development Zone Pilot Area
Phone: +86 7682852923p:+86 7682852923 CHAOZHOU, GNG  521000  China Ticker: 300639300639
Business Summary
Guangdong Hybribio Biotech Co Ltd is a China-based company primarily engaged in the manufacture and sales of in vitro diagnostic reagents. The Company operates through three segments. The In Vitro Diagnostic Reagents, Supporting Instruments, and Consumables segment focuses on the research, development, and production of nucleic acid detection reagents and associated instrumentation, including product series for cervical cancer screening, genetic susceptibility testing for hearing loss, and others. The Medical Testing Services segment provides medical laboratory services to healthcare institutions, offering a comprehensive range of testing items that encompass genetic and metabolic disorders, infectious diseases, molecular pathology, and oncology diagnostics. The Medical Services segment primarily delivers precise and personalized solutions for health risk assessment, disease treatment, and health management.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories
8099 Health and allied services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board QiaozhongGuan 75 9/1/2022
Vice Chairman of the Board WeixiongHuang 61 9/1/2022
Chief Financial Officer QinghuiLi 59 4/24/2014 4/24/2014
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2,205 (As of 12/31/2024)
Outstanding Shares: 646,500,674 (As of 9/30/2025)
Shareholders: 32,805
Stock Exchange: SHE
Fax Number: +86 7682852920


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026